- $110.41m
- -$91.26m
- $149.96m
- 25
- 54
- 26
- 27
Annual income statement for MacroGenics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 105 | 77.4 | 152 | 58.7 | 150 |
| Cost of Revenue | |||||
| Gross Profit | — | 74.8 | 145 | 50.5 | 138 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 236 | 280 | 273 | 76.1 | 224 |
| Operating Profit | -131 | -203 | -121 | -17.3 | -74.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -130 | -202 | -120 | -9.06 | -66 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -130 | -202 | -120 | -9.06 | -67 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -130 | -202 | -120 | -9.06 | -67 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -130 | -202 | -120 | -9.06 | -67 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.47 | -3.37 | -1.95 | -2.58 | -1.45 |